After attending this educational activity, learners should be better able to:
1. Review the causes and underlying pathophysiology of anemia in patients with CKD
2. Assess current options for treating anemia in patients with CKD
3. Describe the role of hypoxia inducible factor (HIF) in CKD anemia and the rationale for developing therapy that targets prolyl hydroxylase (PH)
4. Evaluate emerging data and clinical implications of HIF stabilization/PH inhibition as a strategy to address anemia in CKD
5. Review the pharmacist role in patient care and management of therapy options
This activity has been developed for the pharmacist engaged in the care of patients with chronic kidney disease.